Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases

Jonathan Pol; Juliette Paillet; Céleste Plantureux; Guido Kroemer

doi:10.1080/2162402X.2022.2029299

Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases

Oncoimmunology. 2022 Jan 18;11(1):2029299. doi: 10.1080/2162402X.2022.2029299. eCollection 2022.

Authors

Jonathan Pol^{1

2}, Juliette Paillet^{1

2}, Céleste Plantureux^{1

2

3}, Guido Kroemer^{1

2

4

5

6

7}

Affiliations

¹ Equipe 11 Labellisée Par La Ligue Nationale Contre Le Cancer, Centre de Recherche Des Cordeliers, Inserm U1138, Université de Paris, Sorbonne Université, Paris, France.
² Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
³ Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, France.
⁴ Institut Universitaire de France, Paris, France.
⁵ Pôle de Biologie, Hôpital Européen Georges Pompidou, Ap-hp, Paris, France.
⁶ Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
⁷ Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

Abstract

Chronic inflammation drives proliferative responses, hence increasing cellular multiplication with the consequent risk of malignant transformation. Autoimmune responses against self-antigens drive chronic inflammation but may also enhance cancer immunosurveillance with the consequent reduction of tumor incidence and progression. These notions, which have been well established at the preclinical level, may explain the generally positive associations between immune-inflammatory diseases but also some negative associations, for example between breast cancer and rheumatoid arthritis or systemic lupus erythematosus, which have recently been confirmed in a study enrolling close to half a million participants from the UK Biobank.

Keywords: Cancer; autoimmunity; immunosurveillance; inflammation.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Rheumatoid* / epidemiology
Autoimmunity
Humans
Inflammation / epidemiology
Lupus Erythematosus, Systemic*
Neoplasms* / epidemiology

Grants and funding

JGP is supported by the Association Française d’Hépatologie (AFEF); SIRIC Cancer Research and Personalized Medicine (CARPEM); Multi-Organism Institute (ITMO) Aviesan Cancer (National Alliance for Life Sciences and Health), Institut National du Cancer (INCa), and Fondation pour la Recherche Médicale (FRM). CP is supported by the Fondation pour la Recherche Médicale (FRM). GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the RHU Torino Lumière; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001.